In the past six months, BioVie has gained considerable attention from the market due to NE3107’s promising clinical findings in Alzheimer’s disease (AD) and Parkinson’s disease (PD). These findings were further bolstered by the recent announcement of statistically significant and robust efficacy data for BIV-201 in patients with refractory ascites. Both clinical candidates are in the advanced clinical phase and have the potential to address significant unmet needs in their respective therapeutic areas. In its BioVie Day presentation, the company explained in detail the historical clinical findings, current progress of the clinical pipeline, and future course of action. Aside from these, the company reaffirmed its confidence in NE3107’s potent dual mechanism of action (MoA) and emphasized a U.S. market potential exceeding $30 billion for NE3107. This article highlights the additional clinical findings from the PD trial and ascites trial, updates on the AD/mild cognitive impairment (MCI) clinical trial, and additional updates from the company’s BioVie Day presentation.
